COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #176
Source   PDF   Share   Tweet
See all 181 studies
Late treatment study
Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223 (Preprint)
Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience
Retrospective 976 hospitalized patients with 834 treated with HC Q+AZ showing HC Q mortality relative risk RR 0.35, p < 0.0001. Note that in this case HC Q was recommended for mild/moderate cases, so more severe cases may not have received HC Q (which may also be why they became severe cases). We note that this is opposite to a common bias in HC Q studies - in many cases HC Q was more likely to be given to more severe cases.
death, ↓65.4%, p<0.0001
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.